Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05841563 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
A Phase 1 study of Advanced Solid Tumor, sponsored by PharmaMar.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 125
- Enrollment target
- 3
- Study locations
NCT05841563: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by PharmaMar.
NCT05841563 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by PharmaMar. The registered enrollment target is 125 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (35% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05841563, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by PharmaMar.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 125 participants
- Enrollment target
- 3
- Study locations
Study Summary
The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54. The second part of the study (phase Ib - safety run-in and expansion) will be to reassess the maximum tolerated dose (MTD) defined in the Phase Ia stage in a framework of more extensive premedication, and to evaluate the antitumor activity of PM54 according to the RECIST v.1.1 (or mRECIST v.1.1 in case of MPM) and/or serum markers as appropriate, in patients with selected advanced solid tumors.
Conditions Studied
Interventions
- DRUG PM54
Study Locations (3)
Texas
- South Texas Accelerated Research Therapeutics - San Antonio
Other
- Institut Jules Bordet - Anderlecht
M
- HM Universitario Sanchinarro - Madrid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2023-04-28 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 1 |
What NCT05841563 shows while recruiting
NCT05841563 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which PM54 is the first listed.
NCT05841563 reports a single indexed study location in Texas, Other, M.
Frequently Asked Questions
What is clinical trial NCT05841563 about?
NCT05841563 is a clinical study titled "Clinical Trial of PM54 in Advanced Solid Tumors Patients.". The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54. The second part of the study (phase Ib - safety run-in and expansion) will be to reassess the maximum tolerated dose (MTD) defined in the Phas...
What is the current status of trial NCT05841563?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2023-04-28. Estimated completion is 2027-04-30.
What conditions does trial NCT05841563 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT05841563?
The interventions under investigation include: PM54 (DRUG).
Who is sponsoring clinical trial NCT05841563?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05841563 being conducted?
This trial has 3 study locations across Texas, M. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05841563's enrollment target sits among peer trials
125 101st of 189 higher than 88 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI